CRISPR Therapeutics Schedules May 12 Conference, Reports 500+ Q1 Casgevy Starts and H2 Phase 1 Catalysts
CRISPR Therapeutics will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12 at 1:40 pm PDT via live webcast and 14-day archive. Casgevy exa-cel patient initiations topped 500 in Q1 despite revenue declines, and autoimmune and in-vivo gene-editing Phase 1 catalysts are expected in H2.
1. Conference Presentation Details
CRISPR Therapeutics’ senior management will present a fireside chat at the Bank of America Securities 2026 Global Healthcare Conference on May 12 at 1:40 pm PDT. A live webcast will be accessible on the company’s website with a replay archived for 14 days following the event.
2. Q1 Casgevy Performance
In the first quarter, over 500 patients initiated treatment with Casgevy exa-cel, marking continued patient adoption despite a sequential decline in revenue. The company highlighted Casgevy’s multibillion-dollar addressable market in sickle cell disease and transfusion-dependent beta thalassemia.
3. Pipeline Catalysts and Outlook
CRISPR Therapeutics is advancing autoimmune disease and in-vivo gene-editing programs, with several Phase 1 data readouts expected in the second half of 2026. Strategic collaborations and platform expansions through SyNTase™ editing aim to drive future growth across multiple therapeutic areas.